Antagonist (farmakologija) (Serbian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Antagonist (farmakologija)" in Serbian language version.

refsWebsite

Global rank Serbian rank

9nih.gov

4^th place

8^th place

8doi.org

2^nd place

4^th place

4semanticscholar.org

11^th place

23^rd place

1uam.es

7,583^rd place

low place

1archive.org

6^th place

5^th place

archive.org

Kenakin, Terrence P.; Kenakin, Terry (2006). A pharmacology primer: theory, application, and methods. Amsterdam: Elsevier/Academic Press. ISBN 978-0-12-370599-0.

doi.org

Hopkins AL, Groom CR (2002). „The druggable genome”. Nature Reviews. Drug Discovery. 1 (9): 727—30. PMID 12209152. S2CID 13166282. doi:10.1038/nrd892.
Dorph-Petersen KA, Pierri JN, Perel JM, Sun Z, Sampson AR, Lewis DA (2005). „The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys”. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 30 (9): 1649—61. PMID 15756305. S2CID 205679212. doi:10.1038/sj.npp.1300710.
May LT, Avlani VA, Sexton PM, Christopoulos A (2004). „Allosteric modulation of G protein-coupled receptors”. Curr. Pharm. Des. 10 (17): 2003—13. PMID 15279541. S2CID 36602982. doi:10.2174/1381612043384303.
Christopoulos, A (2002). „Allosteric binding sites on cell-surface receptors: novel targets for drug discovery”. Nature Reviews. Drug Discovery. 1 (3): 198—210. PMID 12120504. S2CID 13230838. doi:10.1038/nrd746.
Bleicher KH, Green LG, Martin RE, Rogers-Evans M (2004). „Ligand identification for G-protein-coupled receptors: a lead generation perspective”. Curr Opin Chem Biol. 8 (3): 287—96. PMID 15183327. doi:10.1016/j.cbpa.2004.04.008.
Rees S, Morrow D, Kenakin T (2002). „GPCR drug discovery through the exploitation of allosteric drug binding sites”. Recept. Channels. 8 (5–6): 261—8. PMID 12690954. doi:10.1080/10606820214640.
Negus, SS (2006). „Some implications of receptor theory for in vivo assessment of agonists, antagonists and inverse agonists”. Biochem. Pharmacol. 71 (12): 1663—70. PMC 1866283 . PMID 16460689. doi:10.1016/j.bcp.2005.12.038.
Stephenson, RP (1997). „A modification of receptor theory. 1956”. Br. J. Pharmacol. 120 (4 Suppl): 106—20; discussion 103—5. PMC 3224279 . PMID 9142399. doi:10.1111/j.1476-5381.1997.tb06784.x. . PMC 1510558  //www.ncbi.nlm.nih.gov/pmc/articles/PMC1510558. Недостаје или је празан параметар |title= (помоћ) of the original article.

nih.gov

ncbi.nlm.nih.gov

Hopkins AL, Groom CR (2002). „The druggable genome”. Nature Reviews. Drug Discovery. 1 (9): 727—30. PMID 12209152. S2CID 13166282. doi:10.1038/nrd892.
Dorph-Petersen KA, Pierri JN, Perel JM, Sun Z, Sampson AR, Lewis DA (2005). „The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys”. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 30 (9): 1649—61. PMID 15756305. S2CID 205679212. doi:10.1038/sj.npp.1300710.
May LT, Avlani VA, Sexton PM, Christopoulos A (2004). „Allosteric modulation of G protein-coupled receptors”. Curr. Pharm. Des. 10 (17): 2003—13. PMID 15279541. S2CID 36602982. doi:10.2174/1381612043384303.
Christopoulos, A (2002). „Allosteric binding sites on cell-surface receptors: novel targets for drug discovery”. Nature Reviews. Drug Discovery. 1 (3): 198—210. PMID 12120504. S2CID 13230838. doi:10.1038/nrd746.
Bleicher KH, Green LG, Martin RE, Rogers-Evans M (2004). „Ligand identification for G-protein-coupled receptors: a lead generation perspective”. Curr Opin Chem Biol. 8 (3): 287—96. PMID 15183327. doi:10.1016/j.cbpa.2004.04.008.
Rees S, Morrow D, Kenakin T (2002). „GPCR drug discovery through the exploitation of allosteric drug binding sites”. Recept. Channels. 8 (5–6): 261—8. PMID 12690954. doi:10.1080/10606820214640.
Negus, SS (2006). „Some implications of receptor theory for in vivo assessment of agonists, antagonists and inverse agonists”. Biochem. Pharmacol. 71 (12): 1663—70. PMC 1866283 . PMID 16460689. doi:10.1016/j.bcp.2005.12.038.
Ariëns, EJ (1954). „Affinity and intrinsic activity in the theory of competitive inhibition. I. Problems and theory”. Archives internationales de pharmacodynamie et de thérapie. 99 (1): 32—49. PMID 13229418.
Stephenson, RP (1997). „A modification of receptor theory. 1956”. Br. J. Pharmacol. 120 (4 Suppl): 106—20; discussion 103—5. PMC 3224279 . PMID 9142399. doi:10.1111/j.1476-5381.1997.tb06784.x. . PMC 1510558  //www.ncbi.nlm.nih.gov/pmc/articles/PMC1510558. Недостаје или је празан параметар |title= (помоћ) of the original article.

semanticscholar.org

api.semanticscholar.org

Hopkins AL, Groom CR (2002). „The druggable genome”. Nature Reviews. Drug Discovery. 1 (9): 727—30. PMID 12209152. S2CID 13166282. doi:10.1038/nrd892.
Dorph-Petersen KA, Pierri JN, Perel JM, Sun Z, Sampson AR, Lewis DA (2005). „The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys”. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 30 (9): 1649—61. PMID 15756305. S2CID 205679212. doi:10.1038/sj.npp.1300710.
May LT, Avlani VA, Sexton PM, Christopoulos A (2004). „Allosteric modulation of G protein-coupled receptors”. Curr. Pharm. Des. 10 (17): 2003—13. PMID 15279541. S2CID 36602982. doi:10.2174/1381612043384303.
Christopoulos, A (2002). „Allosteric binding sites on cell-surface receptors: novel targets for drug discovery”. Nature Reviews. Drug Discovery. 1 (3): 198—210. PMID 12120504. S2CID 13230838. doi:10.1038/nrd746.

uam.es

pdg.cnb.uam.es

GlaxoWellcome. „Pharmacology Guide: In vitro pharmacology: concentration-response curves”.